Vanda stock analysis
Vanda (0LKB) Share Price & Analysis
0LKB Stock Chart & Stats
- Day’s Range
- $3.80 - $3.90
- 52-Week Range
- $3.60 - $10.24
- Previous Close
- $3.81
- Volume
- N/A
- Average Volume (3M)
- 7,219
- Market Cap
- $226.76M
- Enterprise Value
- $178.36M
- Total Cash (Recent Filing)
- $140.49M
- Total Debt (Recent Filing)
- $21.97M
- Price to Earnings (P/E)
- ―
- Beta
- 1.27
- Next Earnings
- Feb 10, 2027 (Est.)
- EPS Estimate
- -0.3
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Fanapt Commercial Momentum
Fanapt is showing durable commercial traction following its bipolar I expansion, with higher sales, prescriptions, and new-to-brand demand. Continued volume growth and broader prescriber reach can support recurring revenue and help establish a stronger base before future exclusivity pressure emerges.
Protected BYSANTI Growth Opportunity
BYSANTI adds an approved product with a planned near-term launch and substantial stated exclusivity protection. Its indications overlap with Fanapt, creating an opportunity to build a durable commercial franchise while improving product continuity ahead of Fanapt's expected loss of exclusivity.
Low Balance-sheet Leverage
Very low leverage reduces fixed financial obligations and gives Vanda more balance-sheet flexibility than a highly indebted biotechnology company. This cushion can help support commercialization and development decisions, although its value depends on slowing losses and preserving available liquidity.
Bears Say
Severe Profitability Deterioration
The move from near-breakeven results in 2024 to heavy losses in 2025 and the TTM period indicates that revenue is not currently supporting the operating structure. Persistent negative margins can weaken internal funding capacity and make future growth increasingly dependent on cash reserves or external financing.
Accelerating Cash Burn
The sharp decline in cash resources, combined with management's expectation of higher full-year burn, raises a durable funding and runway concern. Continued spending on launches and development may consume liquidity before newer products generate meaningful revenue, limiting strategic flexibility.
HETLIOZ Generic Pressure
HETLIOZ is facing an established competitive erosion that has already reduced year-to-date sales, and management warned declines could become significant. This creates a persistent headwind for the existing revenue base and places greater pressure on Fanapt and pipeline launches to offset the shortfall.
Vanda News
Vanda’s Tasimelteon Study Completion: What Sleep Trial Progress Means for VNDA Investors
Vanda Pharmaceuticals ($VNDA) announced an update on their ongoing clinical study. The study, “A Multicenter, Double-blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in Participants With Delayed
0LKB FAQ
What was Vanda’s price range in the past 12 months?
What is Vanda’s market cap?
When is Vanda’s upcoming earnings report date?
How were Vanda’s earnings last quarter?
Is Vanda overvalued?
Does Vanda pay dividends?
What is Vanda’s EPS estimate?
How many shares outstanding does Vanda have?
What happened to Vanda’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Vanda?
What is the TipRanks Smart Score and how is it calculated?
Vanda Stock Smart Score
Company Description
Vanda
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mihael H. Polymeropoulos
- Employees
- 533
- Website
- www.vandapharma.com
- Address
- 2200 Pennsylvania Avenue NW, Washington, DC, 20037, US
Vanda (0LKB) Earnings & Revenues
0LKB Earnings Call
Earnings Call SentimentPositive
The call was broadly positive, supported by 24% third-quarter revenue growth, strong Fanapt prescription trends, positive NEREUS and HETLIOZ clinical results, the expected BYSANTI launch, the Quimilza regulatory milestone, and declining quarterly operating expenses. These positives were partly offset by a larger year-to-date net loss, a substantial cash balance decline, expected higher 2026 cash burn, continued generic pressure on HETLIOZ, constrained early NEREUS revenue, and ongoing regulatory proceedings.
View all GB:0LKB earnings summaries0LKB Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |















